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Essentials
• Trends in adoption of direct oral anticoagulants for venous thromboembolism (VTE) treatment are not documented.
• VTE cases were identified from a large US administrative data source for the years 2012 to 2017.
• Warfarin was prescribed to 98.7% in quarter 1 of 2012 but only 17.5% in quarter 4 of 2017.
• By quarter 4 of 2017, 42.7% of VTE patients were prescribed rivaroxaban and 38.6% apixaban.
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| INTRODUCTION
Over 1 million Americans annually experience venous thromboembolism (VTE), which consists of both deep vein thrombosis and pulmonary embolism. After decades in which vitamin K antagonists (warfarin in the United States) were the mainstay for primary treatment of VTE, options have expanded with the advent and regulatory approval of several direct oral anticoagulants (DOACs) to treat VTE. [1] [2] [3] [4] [5] [6] 
| METHODS
The present analysis used IBM MarketScan Commercial Claims Individuals working at small companies are also underrepresented.
Given the deidentified nature of the MarketScan data, this analysis was deemed exempt from review by the University of Minnesota Institutional Review Board.
| Identification of VTE cases
The present analysis includes individuals aged 18 to 99 with incident VTE, at least 1 prescription for an OAC within the 31 days before or after their first VTE claim (due to nuances of dates in claims-based data), and ≥3 months of continuous enrollment prior to their first OAC prescription. As in previous work, 9 we defined VTE as having at least 1 inpatient claim for VTE or 2 outpatient claims for VTE, which were 7 to 185 days apart, in any position, based on International Classification of Diseases (ICD) 9th and 10th
Revision codes. The positive predictive value (PPV) of this definition was 91% in a recent validation study that employed a definition similar to that used in this analysis, which was inclusive of both inpatient and outpatient encounters and additionally required treatment. 
| Anticoagulant use
Prescriptions for DOACs and warfarin were identified using outpatient pharmaceutical claims data, which include information on the National Drug Code, the prescription fill date, and the number of days supplied. Validity of warfarin claims in administrative databases is excellent (sensitivity, 94%; PPV, 99%). 
| Statistical analysis
This 
| RESULTS AND DISCUSSION
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